These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1176 related items for PubMed ID: 34407851

  • 1. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
    Zhao H, Xing C, Zhang J, He B.
    Reprod Health; 2021 Aug 18; 18(1):171. PubMed ID: 34407851
    [Abstract] [Full Text] [Related]

  • 2. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
    Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH.
    Cochrane Database Syst Rev; 2017 Nov 29; 11(11):CD003053. PubMed ID: 29183107
    [Abstract] [Full Text] [Related]

  • 3. Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS.
    Xing C, Li C, He B.
    J Clin Endocrinol Metab; 2020 Sep 01; 105(9):2950-63. PubMed ID: 32490533
    [Abstract] [Full Text] [Related]

  • 4. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
    Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH.
    Cochrane Database Syst Rev; 2012 May 16; (5):CD003053. PubMed ID: 22592687
    [Abstract] [Full Text] [Related]

  • 5. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.
    Lord JM, Flight IH, Norman RJ.
    Cochrane Database Syst Rev; 2003 May 16; (3):CD003053. PubMed ID: 12917943
    [Abstract] [Full Text] [Related]

  • 6. The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-analysis.
    Yang S, Zhao L, He W, Mi Y.
    Drugs; 2022 Sep 16; 82(14):1469-1480. PubMed ID: 36129662
    [Abstract] [Full Text] [Related]

  • 7. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
    Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH.
    Cochrane Database Syst Rev; 2010 Jan 20; (1):CD003053. PubMed ID: 20091537
    [Abstract] [Full Text] [Related]

  • 8. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome.
    Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N.
    Cochrane Database Syst Rev; 2007 Jan 24; (1):CD005552. PubMed ID: 17253562
    [Abstract] [Full Text] [Related]

  • 9. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
    Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH.
    Cochrane Database Syst Rev; 2009 Oct 07; (4):CD003053. PubMed ID: 19821299
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial.
    Jethaliya H, Gajjar N, Patel V, Deshpande S, Patel R.
    Reprod Sci; 2022 Aug 07; 29(8):2282-2298. PubMed ID: 35477841
    [Abstract] [Full Text] [Related]

  • 11. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS).
    Fruzzetti F, Perini D, Russo M, Bucci F, Gadducci A.
    Gynecol Endocrinol; 2017 Jan 07; 33(1):39-42. PubMed ID: 27808588
    [Abstract] [Full Text] [Related]

  • 12. The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria.
    Pustotina O, Myers SH, Unfer V, Rasulova I.
    Gynecol Obstet Invest; 2024 Jan 07; 89(2):131-139. PubMed ID: 38295772
    [Abstract] [Full Text] [Related]

  • 13. A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome.
    Nazirudeen R, Sridhar S, Priyanka R, Sumathi B, Natarajan V, Subbiah E, Raghavan KS, Sangumani J.
    Clin Endocrinol (Oxf); 2023 Aug 07; 99(2):198-205. PubMed ID: 37265016
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients.
    Minozzi M, Nordio M, Pajalich R.
    Eur Rev Med Pharmacol Sci; 2013 Feb 07; 17(4):537-40. PubMed ID: 23467955
    [Abstract] [Full Text] [Related]

  • 16. Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial.
    Shokrpour M, Foroozanfard F, Afshar Ebrahimi F, Vahedpoor Z, Aghadavod E, Ghaderi A, Asemi Z.
    Gynecol Endocrinol; 2019 May 07; 35(5):406-411. PubMed ID: 30608001
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Insulin sensitizers in adolescents with polycystic ovary syndrome.
    LE TN, Wickham EP, Nestler JE.
    Minerva Pediatr; 2017 Oct 07; 69(5):434-443. PubMed ID: 28497664
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. WITHDRAWN: Insulin-sensitising drugs for polycystic ovary syndrome.
    Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH.
    Cochrane Database Syst Rev; 2009 Jul 08; (3):CD003053. PubMed ID: 19588338
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.